Anterior gradient protein: Difference between revisions
No edit summary |
No edit summary |
||
| Line 25: | Line 25: | ||
The AGR2 protein can form complexes with Reptin which is recognized as an anti-oncogene. However, it binds more easily when the protein is in dimeric form. Thus, a mutation on (<scene name='87/872187/Agr2_e60/2'>E60</scene>) site, giving the protein a monomeric form, would reduce cancer repression by Reptin. | The AGR2 protein can form complexes with Reptin which is recognized as an anti-oncogene. However, it binds more easily when the protein is in dimeric form. Thus, a mutation on (<scene name='87/872187/Agr2_e60/2'>E60</scene>) site, giving the protein a monomeric form, would reduce cancer repression by Reptin. | ||
Finally, the expression of AGR2 in breast cancer patients confers chemoresistance to cancer cell growth inhibitors such as Tamoxifen, the mechanism is still uncelar.<ref>PMID: 25937245</ref> | Finally, the expression of AGR2 in breast cancer patients confers chemoresistance to cancer cell growth inhibitors such as Tamoxifen, the mechanism is still uncelar.<ref>PMID: 25937245</ref> | ||
</StructureSection> | |||
== References == | == References == | ||
<references/> | <references/> | ||